These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 443660)

  • 41. Investigational new drug regs: icing or cake?
    Margolis RE
    Healthspan; 1988 Dec; 5(11):25-6. PubMed ID: 10291398
    [No Abstract]   [Full Text] [Related]  

  • 42. Identification of adverse reactions to new drugs. II (continued): How were 18 important adverse reactions discovered and with what delays?
    Venning GR
    Br Med J (Clin Res Ed); 1983 Jan; 286(6362):365-8. PubMed ID: 6402104
    [No Abstract]   [Full Text] [Related]  

  • 43. Defining the pharmaceutical system to support proactive drug safety.
    Lewis VR; Hernandez A; Meadors M
    Curr Drug Saf; 2013 Feb; 8(1):25-39. PubMed ID: 23656445
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Diagnostic kits in parasitology: which controls?].
    Rossi P
    Parassitologia; 2004 Jun; 46(1-2):145-9. PubMed ID: 15305705
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The Institute of Medicine's report on drug safety: constructive and ambitious, but does it go far enough?
    Jones JK
    Clin Pharmacol Ther; 2007 Feb; 81(2):156-8. PubMed ID: 17259940
    [TBL] [Abstract][Full Text] [Related]  

  • 46. What can be done to improve confidence and trust in the safety of the system for pharmaceutical products?
    Edwards BD; Whalen MD; Powell SM
    Curr Drug Saf; 2013 Feb; 8(1):1-3. PubMed ID: 23713998
    [No Abstract]   [Full Text] [Related]  

  • 47. Evaluation of spontaneous reports of adverse reactions to drugs.
    Inman WH; Evans DA
    Br Med J; 1972 Sep; 3(5829):746-9. PubMed ID: 5077919
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Impact of Expanded Access on FDA Regulatory Action and Product Labeling.
    Jarow JP; Moscicki R
    Ther Innov Regul Sci; 2017 Nov; 51(6):787-789. PubMed ID: 30079277
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The safety of new drugs.
    Hull CJ
    Br J Anaesth; 1989 Jun; 62(6):587-9. PubMed ID: 2751914
    [No Abstract]   [Full Text] [Related]  

  • 50. Report of the Institute of Medicine Committee on the Efficacy and Safety of Halcion.
    Bunney WE; Azarnoff DL; Brown BW; Cancro R; Gibbons RD; Gillin JC; Hullett S; Killam KF; Kupfer DJ; Krystal JH; Stolley PD; French GS; Pope AM
    Arch Gen Psychiatry; 1999 Apr; 56(4):349-52. PubMed ID: 10197830
    [No Abstract]   [Full Text] [Related]  

  • 51. The need to improve hospital investigational drug policies and procedures.
    Stolar MH
    Hosp Formul; 1983 Jan; 18(1):79-82. PubMed ID: 10258324
    [No Abstract]   [Full Text] [Related]  

  • 52. Post-marketing studies: the work of the Drug Safety Research Unit.
    Mackay FJ
    Drug Saf; 1998 Nov; 19(5):343-53. PubMed ID: 9825948
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The current status of guidelines for clinical research from the viewpoint of the pharmaceutical industry.
    Dixon RB
    J Clin Pharmacol; 1977; 17(11-12):691-6. PubMed ID: 925189
    [No Abstract]   [Full Text] [Related]  

  • 54. Symposium on drug safety. The role of regulatory agencies and industry in assessment of the safety of drugs for use in man. The situation in the United Kingdom.
    Cahal DA
    Can Med Assoc J; 1968 Feb; 98(6):271-5. PubMed ID: 5636096
    [No Abstract]   [Full Text] [Related]  

  • 55. A definitive or thorough phase 1 QT ECG trial as a requirement for drug safety assessment.
    Morganroth J
    J Electrocardiol; 2004 Jan; 37(1):25-9. PubMed ID: 15132366
    [TBL] [Abstract][Full Text] [Related]  

  • 56. History and application of drug safety and efficacy requirements in the United States.
    Wardell WM
    Agents Actions; 1978 Jun; 8(4):420-1. PubMed ID: 356565
    [No Abstract]   [Full Text] [Related]  

  • 57. The "treatment IND (investigational new drugs)": public policy considerations.
    Roberts C; Palumbo FB
    J Pharm Mark Manage; 1988; 3(1):41-59. PubMed ID: 10290888
    [TBL] [Abstract][Full Text] [Related]  

  • 58. International regulatory aspects of clinical periodontal research.
    Cooley WE; Castellion AW
    Ann Periodontol; 1997 Mar; 2(1):18-30. PubMed ID: 9151540
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Age and sex distribution of suspected adverse drug reactions to newly marketed drugs in general practice in England: analysis of 48 cohort studies.
    Martin RM; Biswas PN; Freemantle SN; Pearce GL; Mann RD
    Br J Clin Pharmacol; 1998 Nov; 46(5):505-11. PubMed ID: 9833605
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Assessment of drug metabolites.
    Izumi T
    Drug Metab Pharmacokinet; 2011; 26(2):121-2. PubMed ID: 21532211
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.